ClinicalTrials.gg
CompletedNCT02545049FIGARO-DKDUpdated Apr 15, 2022Results posted

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

A Phase 3 interventional study of Finerenone (BAY94-8862) and Placebo in Diabetic Kidney Disease, sponsored by Bayer. Completed at 975 sites in 48 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-15.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7,352
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing finerenone in Diabetic Nephropathies — 5 open to participants now, 5 under way, 1 of them phase 3. finerenone · Diabetic Nephropathies.

Enrollment
Largest of 10
7,352 · median 108
Started
2015
with 1 other
Phase 3
3 of 10
1 open now
Registered
3rd of 10
by date
Lead sponsor
5 of 10
Bayer

Among the 10 studies testing finerenone in Diabetic Nephropathies, this one has the largest enrollment, is one of 2 that started in 2015, is one of 3 in phase 3, and was the 3rd registered.

Diabetic Nephropathies

543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

5 of the 10 studies testing finerenone in Diabetic Nephropathies are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing finerenone in Diabetic Nephropathies, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.

03

Conditions studied

  • Diabetic Kidney Disease

Keywords

  • Type 2 Diabetes
  • Kidney diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women ≥18 years of age
  • Subjects with Type Type 2 Diabetes Mellitus as defined by the American Diabetes Association
  • Diagnosis of Diabetic Kidney Disease with persistent high albuminuria or persistent very high albuminuria at the Run-In and Screening Visit
  • Pretreated with either angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at maximal tolerated labeled dose without adjustments
  • Serum potassium \<=4.8 mmol/L

Exclusion criteria

Exclusion Criteria:

  • Confirmed significant non-diabetic renal disease, including renal artery stenosis
  • Uncontrolled arterial hypertension (ie, mean sitting systolic blood pressure (SBP) ≥170 mmHg or mean sitting diastolic blood pressure(DBP) ≥110 mmHg at run in visit, or mean sitting SBP ≥160 mmHg or mean sitting DBP ≥100 mmHg at screening)
  • Clinical diagnosis of chronic heart failure with reduced (HFrEF) and persistent symptoms { (NYHA) class II - IV} at Run in visit [class 1A recommendation for mineralcorticoid receptor antagonist (MRAs)]
  • Dialysis for acute renal failure within 12 weeks of Run-in visit
  • Renal allograft in place or scheduled kidney transplant within next 12 months
  • (HbA1c) >12%
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
7,352 participants (actual)

Study arms

  • Experimental
    BAY94-8862

    Finerenone tablet

    Drug: Finerenone (BAY94-8862)

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • 10 mg or 20 mg Finerenone tablet to be given orally, once daily.

  • DrugPlacebo

    Matching placebo to be taken orally, once daily.

06

What researchers measure

Primary outcomes

  1. The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.

    Number of participants with the first occurrence of the primary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were reported as descriptive result.

    Time frame: From randomization up until the first occurrence of the CV composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.

Secondary outcomes

  1. The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death.

    Number of participants with first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were reported as descriptive result.

    Time frame: From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.

  2. All-cause Hospitalization

    Number of participants with first occurrence of a hospitalization event were reported as descriptive result.

    Time frame: From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average study duration of 41 months

  3. All-cause Mortality

    Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table.

    Time frame: From randomization up until death due to any cause, or censoring at the end of the study, with an average study duration of 41 months

  4. Change in Urinary Albumin-to-creatine Ratio (UCAR) From Baseline to Month 4

    First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change.

    Time frame: From baseline up until Month 4

  5. The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death

    Number of participants with first occurrence of the renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were reported as descriptive result.

    Time frame: From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months

07

Results

Posted Apr 15, 2022

Participant flow

Study was conducted at multiple centers in 48 countries/regions between 17-Sep-2015 (first participant first visit) and 02-Feb-2021 (last participant last visit).

Participant flow — Overall Study
MilestoneFinerenonePlacebo
Started37233714
Treated36833658
Included in fas36863666
Completed36813653
Not completed4261
Withdrew: Withdrawal by subject17
Withdrew: Lost to follow-up46
Withdrew: Gcp violations3748

Outcome measures

PrimaryThe First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.

Number of participants with the first occurrence of the primary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were reported as descriptive result.

Time frame:
From randomization up until the first occurrence of the CV composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.
Reported as:
Count of participants · Participants
The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.
ParticipantsFinerenonePlacebo
The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.458519
Statistical analysis
  • Finerenone vs Placebo · Log Rank · p = 0.0264 (A hierarchical testing procedure was used for the primary and secondary efficacy endpoints with each variable being tested at the adjusted two-sided significance level of 0.04967388.) · Hazard ratio (hr): 0.87 · 95% CI 0.76 to 0.98A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.
SecondaryThe First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death.

Number of participants with first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were reported as descriptive result.

Time frame:
From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months.
Reported as:
Count of participants · Participants
The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death.
ParticipantsFinerenonePlacebo
The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death.350395
Statistical analysis
  • Finerenone vs Placebo · Log Rank · p = 0.0689 (A hierarchical testing procedure was used for the primary and secondary efficacy endpoints with each variable being tested at the adjusted two-sided significance level of 0.04967388.) · Hazard ratio (hr): 0.87 · 95% CI 0.76 to 1.01A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.
SecondaryAll-cause Hospitalization

Number of participants with first occurrence of a hospitalization event were reported as descriptive result.

Time frame:
From randomization up until the first occurrence of the hospitalization due to any cause, or censoring at the end of study, with an average study duration of 41 months
Reported as:
Count of participants · Participants
All-cause Hospitalization
ParticipantsFinerenonePlacebo
All-cause Hospitalization15731605
Statistical analysis
  • Finerenone vs Placebo · Log Rank · p = 0.3558 (A hierarchical testing procedure was used for the primary and secondary efficacy endpoints with each variable being tested at the adjusted two-sided significance level of 0.04967388.) · Hazard ratio (hr): 0.97 · 95% CI 0.90 to 1.04A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.
SecondaryAll-cause Mortality

Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table.

Time frame:
From randomization up until death due to any cause, or censoring at the end of the study, with an average study duration of 41 months
Reported as:
Count of participants · Participants
All-cause Mortality
ParticipantsFinerenonePlacebo
All-cause Mortality333370
Statistical analysis
  • Finerenone vs Placebo · Log Rank · p = 0.1337 (A hierarchical testing procedure was used for the primary and secondary efficacy endpoints with each variable being tested at the adjusted two-sided significance level of 0.04967388.) · Hazard ratio (hr): 0.89 · 95% CI 0.77 to 1.04A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.
SecondaryChange in Urinary Albumin-to-creatine Ratio (UCAR) From Baseline to Month 4

First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change.

Time frame:
From baseline up until Month 4
Reported as:
Least squares mean · Ratio
Change in Urinary Albumin-to-creatine Ratio (UCAR) From Baseline to Month 4
RatioFinerenonePlacebo
Change in Urinary Albumin-to-creatine Ratio (UCAR) From Baseline to Month 40.624 (0.606 to 0.642)0.922 (0.896 to 0.949)
Statistical analysis
  • Finerenone vs Placebo · ANCOVA · p = <0.0001 (P-value from F-test of equal means between the treatment groups. A hierarchical testing procedure was used for the primary and secondary efficacy endpoints with each variable being tested at the adjusted two-sided significance level of 0.04967388.) · Ratio of least squares means: 0.676 · 95% CI 0.650 to 0.704
SecondaryThe First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death

Number of participants with first occurrence of the renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were reported as descriptive result.

Time frame:
From randomization up until the first occurrence of the renal composite endpoint, or censoring at the end of the study, with an average study duration of 41 months
Reported as:
Count of participants · Participants
The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death
ParticipantsFinerenonePlacebo
The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death108139
Statistical analysis
  • Finerenone vs Placebo · Log Rank · p = 0.0406 (A hierarchical testing procedure was used for the primary and secondary efficacy endpoints with each variable being tested at the adjusted two-sided significance level of 0.04967388.) · Hazard ratio (hr): 0.77 · 95% CI 0.60 to 0.99A stratified Cox proportional hazards regression model was used to provide a point estimate of the hazard ratio and a corresponding two-sided 95% confidence interval.

Adverse events

Collected over After the first dose of study drug up to 3 days after any temporary or permanent interruption of study drug, with an average treatment duration of 36 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Finerenone339/3,686 (9.2%)1,158/3,683 (31.4%)1,797/3,683 (48.8%)
Placebo383/3,666 (10.4%)1,215/3,658 (33.2%)1,717/3,658 (46.9%)
Most frequent serious events
Showing 10 of 1,122
Most frequent serious events
EventFinerenonePlacebo
PneumoniaInfections and infestations73/3683113/3658
Acute kidney injuryRenal and urinary disorders38/368346/3658
CellulitisInfections and infestations40/368328/3658
Urinary tract infectionInfections and infestations28/368339/3658
Type 2 diabetes mellitusMetabolism and nutrition disorders33/368325/3658
HypoglycaemiaMetabolism and nutrition disorders17/368328/3658
Diabetes mellitus inadequate controlMetabolism and nutrition disorders27/368317/3658
Diabetic nephropathyRenal and urinary disorders10/368326/3658
Diabetes mellitusMetabolism and nutrition disorders20/368325/3658
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/368324/3658
Most frequent other events
Showing 10 of 13
Most frequent other events
EventFinerenonePlacebo
NasopharyngitisInfections and infestations318/3683327/3658
HyperkalaemiaMetabolism and nutrition disorders322/3683159/3658
HypertensionVascular disorders199/3683296/3658
ArthralgiaMusculoskeletal and connective tissue disorders296/3683260/3658
Oedema peripheralGeneral disorders197/3683278/3658
Back painMusculoskeletal and connective tissue disorders260/3683252/3658
Urinary tract infectionInfections and infestations246/3683220/3658
DiarrhoeaGastrointestinal disorders235/3683220/3658
Upper respiratory tract infectionInfections and infestations225/3683203/3658
AnaemiaBlood and lymphatic system disorders210/3683199/3658

Baseline characteristics

Full analysis set (FAS): the FAS comprised all randomized participants (except those with critical GCP violations).

Age, Continuous
Age, Continuous(Years)FinerenonePlaceboTotal
Mean64.13 ± 9.6764.13 ± 10.0064.13 ± 9.83
Sex: Female, Male
Sex: Female, Male(Participants)FinerenonePlaceboTotal
Female115810892247
Male252825775105
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FinerenonePlaceboTotal
Hispanic or Latino6186031221
Not Hispanic or Latino305830576115
Unknown or Not Reported10616
Race (NIH/OMB)
Race (NIH/OMB)(Participants)FinerenonePlaceboTotal
American Indian or Alaska Native7370143
Asian7157391454
Native Hawaiian or Other Pacific Islander171431
Black or African American113145258
White267226055277
More than one race8786173
Unknown or Not Reported9716
Urinary albumin-to-creatinine ratio (UACR)
Urinary albumin-to-creatinine ratio (UACR)(milligram/gram (mg/g))FinerenonePlaceboTotal
Median302.36 (105.47 to 749.05)315.06 (111.24 to 731.01)308.18 (108.09 to 739.86)
Estimated glomerular filtration rate (eGFR)
Estimated glomerular filtration rate (eGFR)(mL/min/1.73m^2)FinerenonePlaceboTotal
Mean67.62 ± 21.6567.99 ± 21.7467.80 ± 21.69
08

Study locations

975 sites
  • Birmingham, Alabama 35294-2041, United States
  • Fort Payne, Alabama 35967, United States
  • Huntsville, Alabama 35801-4317, United States
  • Mesa, Arizona 85210, United States
  • Phoenix, Arizona 85016, United States
  • Phoenix, Arizona 85032, United States
  • Prescott, Arizona 86301, United States
  • Tucson, Arizona 85723, United States
  • Tucson, Arizona 85724, United States
  • Bakersfield, California 93309, United States
  • Chula Vista, California 91910, United States
  • Dublin, California 94568, United States
  • El Centro, California 92243, United States
  • Fresno, California 93720, United States
  • Fresno, California 93721, United States
  • La Mesa, California 91942, United States
  • Loma Linda, California 92357, United States
  • Los Angeles, California 90017, United States
  • Los Angeles, California 90022, United States
  • Los Angeles, California 90025, United States
  • Los Angeles, California 90073, United States
  • Northridge, California 91325, United States
  • Port Hueneme, California 93041, United States
  • Poway, California 92064, United States
  • Rancho Cucamonga, California 91730, United States
  • Rialto, California 92377, United States
  • Roseville, California 95661, United States
  • San Diego, California 92117, United States
  • Santa Rosa, California 95405, United States
  • Torrance, California 90502, United States
  • Vista, California 92083, United States
  • New Haven, Connecticut 06520, United States
  • Waterbury, Connecticut 06708, United States
  • Fort Lauderdale, Florida 33308, United States
  • Fort Lauderdale, Florida 33312, United States
  • Fort Lauderdale, Florida 33316-1958, United States
  • Hialeah, Florida 33012, United States
  • Hialeah, Florida 33016, United States
  • Hollywood, Florida 33024, United States
  • Jacksonville, Florida 32204, United States
  • Miami Beach, Florida 33140, United States
  • Miami Gardens, Florida 33014, United States
  • Miami Lakes, Florida 33014, United States
  • Miami Lakes, Florida 33016, United States
  • Miami, Florida 33032, United States
  • Miami, Florida 33126, United States
  • Miami, Florida 33130, United States
  • Miami, Florida 33144, United States
  • Miami, Florida 33145, United States
  • Miami, Florida 33155, United States
  • Miami, Florida 33156, United States
  • Miami, Florida 33165, United States
  • Miami, Florida 33173, United States
  • Miami, Florida 33175, United States
  • Miami, Florida 33186, United States
  • New Port Richey, Florida 34652, United States
  • Ocala, Florida 34471, United States
  • Orlando, Florida 32825, United States
  • Palm Harbor, Florida 34684, United States
  • Sarasota, Florida 34239, United States
  • Tampa, Florida 33614, United States
  • West Palm Beach, Florida 33401-3430, United States
  • Winter Haven, Florida 33880, United States
  • Atlanta, Georgia 30303, United States
  • Atlanta, Georgia 30342, United States
  • Augusta, Georgia 30904, United States
  • Lawrenceville, Georgia 30046, United States
  • Macon, Georgia 31210, United States
  • Honolulu, Hawaii 96814, United States
  • Chicago, Illinois 60612, United States
  • Elgin, Illinois 60123, United States
  • Morton, Illinois 61550, United States
  • Springfield, Illinois 62702-1311, United States
  • Indianapolis, Indiana 46202, United States
  • Iowa City, Iowa 52242, United States
  • West Des Moines, Iowa 50265, United States
  • Hutchinson, Kansas 67502-1131, United States
  • Topeka, Kansas 66606, United States
  • Wichita, Kansas 67214, United States
  • Metairie, Louisiana 70006, United States
  • Monroe, Louisiana 71201, United States
  • New Orleans, Louisiana 70112, United States
  • Shreveport, Louisiana 71101, United States
  • Boston, Massachusetts 02215, United States
  • Ann Arbor, Michigan 48109, United States
  • Flint, Michigan 48504, United States
  • Flint, Michigan 48532, United States
  • Kalamazoo, Michigan 49009, United States
  • Minneapolis, Minnesota 55455, United States
  • Columbia, Missouri 65201, United States
  • Columbia, Missouri 65212, United States
  • Jefferson City, Missouri 65109, United States
  • Kansas City, Missouri 64111, United States
  • Kansas City, Missouri 64128, United States
  • Saint Louis, Missouri 63106, United States
  • Saint Louis, Missouri 63136, United States
  • Omaha, Nebraska 68124, United States
  • Omaha, Nebraska 68131, United States
  • Las Vegas, Nevada 89086, United States
  • Las Vegas, Nevada 89102, United States

Showing the first 100 of 975 sites across 48 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B; FIGARO-DKD study investigators. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Am J Nephrol. 2019;50(5):345-356. doi: 10.1159/000503712. Epub 2019 Oct 30. PubMed 31665733 ↗
  • Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. PubMed 34449181 ↗
  • Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, Lambelet M, Lawatscheck R, Bakris GL, Ruilope LM, Agarwal R. Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes. JACC Heart Fail. 2022 Nov;10(11):860-870. doi: 10.1016/j.jchf.2022.07.013. Epub 2022 Oct 12. Erratum In: JACC Heart Fail. 2023 Aug;11(8 Pt 1):1034-1035. doi: 10.1016/j.jchf.2023.06.002. PubMed 36328655 ↗
  • Pitt B, Agarwal R, Anker SD, Ruilope LM, Rossing P, Ahlers C, Brinker M, Joseph A, Lambelet M, Lawatscheck R, Filippatos GS; FIDELIO-DKD and FIGARO-DKD Investigators. Association of Finerenone Use With Reduction in Treatment-Emergent Pneumonia and COVID-19 Adverse Events Among Patients With Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Pooled Secondary Analysis. JAMA Netw Open. 2022 Oct 3;5(10):e2236123. doi: 10.1001/jamanetworkopen.2022.36123. PubMed 36287567 ↗
  • Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A, Pitt B; FIGARO-DKD Investigators. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. Circulation. 2022 Feb 8;145(6):437-447. doi: 10.1161/CIRCULATIONAHA.121.057983. Epub 2021 Nov 13. PubMed 34775784 ↗
  • Erraez S, Lopez-Mesa M, Gomez-Fernandez P. Mineralcorticoid receptor blockers in chronic kidney disease. Nefrologia (Engl Ed). 2021 May-Jun;41(3):258-275. doi: 10.1016/j.nefro.2020.10.001. Epub 2020 Dec 24. English, Spanish. PubMed 33358451 ↗
  • Agarwal R, Anker SD, Bakris G, Filippatos G, Pitt B, Rossing P, Ruilope L, Gebel M, Kolkhof P, Nowack C, Joseph A; FIDELIO-DKD and FIGARO-DKD Investigators. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2022 May 25;37(6):1014-1023. doi: 10.1093/ndt/gfaa294. PubMed 33280027 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, time point and process of data access. As such, Bayer commits to sharing upon request from qualified researcher's patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Feb 2021, 64 months.

Results were first posted in Apr 2022, 1 year 2 months after primary completion.

Of 16 phase 3 interventional studies under Diabetic Nephropathies, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 65. This study's 64 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2015
First posted
Sep 9, 2015
StartActual
Sep 17, 2015
Primary completionActual
Feb 2, 2021
CompletionActual
Feb 2, 2021
Results first posted
Apr 15, 2022
Last update
Apr 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02545049
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 9, 2015
Start date
Sep 17, 2015
Primary completion
Feb 2, 2021
Completion
Feb 2, 2021
Results posted
Apr 15, 2022
Last update
Apr 15, 2022

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion